Mirtazapine, an antidepressant

American Journal of Health-System Pharmacy

Volumn 55, Issue 1, 1998, Pages 44-49

  Puzantian, Talia ^a,b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressants; Costs; Depression; Dosage; Drug interactions; Mechanism of action; Mirtazapine; Pharmacokinetics; Toxicity

Indexed keywords

ALCOHOL; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DIAZEPAM; DOXEPIN; FLUOXETINE; IMIPRAMINE; IMIPRAMINE PAMOATE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN 3 ANTAGONIST; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE;

APPETITE DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO; WEIGHT GAIN;

EID: 0031983375     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.1.44     Document Type: Review

References (21)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994:317-91.
2. Sussman N. The potential benefits of serotonin receptor-specific agents. J Clin Psychiatry. 1994; 55(suppl 2):45-51.
3. Kehoe WA, Schorr RB. Focus on mirtazapine: a new antide-pressant with noradrenergic and specific serotonergic activity. Formulary. 1996; 31:455-69.
4. De Montigny C, Haddjeri N, Mongeau R et al. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs. 1995; 4(suppl 1):13-7.
5. De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996; 57(suppl 4):19-25.
6. 1A-mediated serotonergic neurotransmission. CNS Drugs. 1995;4(suppl 1):29-38.
7. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 1995; 10(suppl 4):37-45.
8. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs. 1995; 4(suppl 1):39-48.
9. Remeron package insert. West Orange, NJ: Organon Inc.; 1996 Apr.
10. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms. Results from a placebo-controlled trial. Drug Invest. 1994; 8:339-44.
11. Sorensen M, Jørgensen J, Viby-Mogensen J et al. A double-blind group comparative study using the new antidepressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand. 1985; 71:339-46.
12. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol. 1995; 10(suppl 4):25-35.
13. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995; 56:519-25.
14. Smith WT, Glaudin V, Panagides J et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull. 1990; 26:191-6.
15. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol. 1995; 10: 173-80.
16. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum Psychopharmacol. 1995; 10(suppl): S135-45.
17. Richou H, Ruimy P, Charbaut J et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol. 1995; 10:263-71.
18. Marttila M, Jääskeläinen J, Järvi R et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol. 1995; 5:441-6.
19. Van Moffaert M, de Wilde J, Vereecken A et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol. 1995; 10:3-9.
20. Stimmel CL, Dopheide JA, Stahl SM. Mirtazapine: an antide-pressant with noradrenergic and specific serotonergic effects. Pharmacotherapy. 1997; 17:10-21.
21. Red book update. 1997 Apr.